NRAS and cancer: To identify neoantigens that might be commonly targeted for the treatment of various types of cancers, we assessed the immunogenicity of 10 well-known driver mutations, including KRAS-G12D, KRAS-G12V, KRAS-G12C, KRAS-G12R, KRAS-G13D, NRAS-Q61K, NRAS-Q61R, PIK3CA-E545K, PIK3CA-H1047R, and C-Kit-D816V.